Salmonella outbreak linked to pistachio products
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
12 minutes ago
- CBC
Union calls for better support for paramedics amid 'profound mental health crisis'
Social Sharing During his more than 30 years as a paramedic in B.C., Terry McManus has had many sleepless nights. "You come home from work and there's something still on your mind. Or you rip a strip off of a waiter or waitress because the ice isn't cold enough. It has nothing to do with the waiter or the ice. It's something you're carrying from last week, or a year ago." McManus, who is now retired from the job, witnessed and experienced trauma every day while out on calls. But he says the support for his and his colleagues' mental health was lacking. "I, personally, have had a counsellor, a mental health professional, tell me to stop the session because the information I was giving them was way too graphic. They didn't like it. That's just one call out of thousands that we want to talk about. It wears on you, and you can't get the help you need." Advocates like McManus are calling for better, urgent mental health support for paramedics amid what the union that represents paramedics and dispatchers describes in a statement as a "profound mental health crisis" within the profession. The president of the Ambulance Paramedics of B.C., which represents about 6,000 paramedics and dispatchers across the province, said in a news release that the union is seeing "unprecedented levels of mental health and wellness claims" among members. The union said recent reports show that 30 per cent of paramedics and dispatchers are off work for mental health reasons or working while actively involved in mental health treatment. It said nine B.C. paramedics have died this year, due to health issues, accidents, and in some cases, by suicide, which the union believes is "very likely" connected to workplace stress. "It's imperative that we look after our people, ensuring they are healthy and safe to come to work, so they can continue to be there for your family members when they need them most, union president Jason Jackson said. "We need solutions, and we need them now." Compounding issues Nicki Ropp, a mental health and wellness co-ordinator for the union, said the last six years in particular have been challenging for paramedics. "With the ongoing opioid crisis that continues to take up a lot of our call volume, the pandemic, the flooding, the heat dome, our staffing shortages, wildfires, everything. This is all compounding things," she said. "And we keep coming back to work, and we keep doing these things and keep showing up." But what isn't happening, she said, is that paramedics aren't getting enough time off to recover from stressful shifts, day in and day out, and they don't have the tools to work through the overlapping traumas. According to the union, paramedics in B.C. responded to nearly one million calls. "I think there's a lot of people who have compassion fatigue, burnout, whatever the word is that we're using, but we are fatigued," Ropp said. "We're tired, that's for sure." 'We have come a long way, but it's not enough' B.C. Emergency Health Services (BCEHS) does provide mental health services for staff, including a team to debrief after traumatic calls and is also available as needed. BCEHS also has an Employee and Family Assistance Program that offers support like counselling for staff and their loved ones, and it has round-the-clock crisis support. WorkSafeBC said it also offers some services, like counselling and access to other mental health specialists. BCEHS chief operations officer Jennie Helmer said she's heard loud and clear from front-line staff that they need more. "We're working on an immediate action plan to introduce more support, more education, more tools that staff are asking for and then working out a longer-term approach as well," she said. McManus said he'd like to see counsellors who are available 24/7 who have experience dealing with the kind of trauma first responders experience. "Maybe they've spent some time working in the emergency departments … they can see what we do and they can feel it a little more and be compassionate and get us the help that we need." Ropp said immediate psychological support should be the priority, and better benefits to allow paramedics and dispatchers to be more proactive about their mental health. "We have come a long way, but it's not enough."
Globe and Mail
41 minutes ago
- Globe and Mail
Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025
NEWTOWN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) ('Traws Pharma', 'Traws' or 'the Company'), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced plans to host a conference call and webcast on Thursday, August 14, 2025 at 8:30 AM ET to discuss financial results for the second quarter ended June 30, 2025 and recent business progress. Conference Call and Webcast Information Date: Thursday, August 14, 2025, at 8:30 AM ET Participant Dial-in (U.S.): 1-877-407-0789 Participant Dial-in (International): 1-201-689-8562 Conference ID: 13754425 Webcast Access: Click Here A replay of the webcast will be available on the Investors section of the Traws website at About Traws Pharma, Inc. Traws Pharma is a clinical stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. Traws integrates antiviral drug development, medical intelligence and regulatory strategy to meet real world challenges in the treatment of viral diseases. We are advancing novel investigational oral small molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health: bird flu and seasonal influenza, and COVID-19/Long COVID. Tivoxavir marboxil is in development as a single dose treatment for bird flu and seasonal influenza, targeting the influenza cap-dependent endonuclease (CEN). Ratutrelvir is in development as a ritonavir-independent COVID treatment, targeting the Main protease (Mpro or 3CL protease). Traws is actively seeking development and commercialization partners for its legacy clinical oncology programs, rigosertib and narazaciclib. More details can be found on Traws' website at For more information, please visit and follow us on LinkedIn. Traws Pharma Contact: Charles Parker Traws Pharma, Inc. cparker@ Investor Contact: John Fraunces LifeSci Advisors, LLC 917-355-2395 jfraunces@
Globe and Mail
an hour ago
- Globe and Mail
DocGo (DCGO) Q2 Revenue Falls 51%
Key Points Revenue (GAAP) of $80.4 million beat analyst estimates by 3.6% in Q2 2025 but was down 51.2% year-over-year (GAAP) in Q2 2025, reflecting the planned wind-down of high-margin government contracts. Net loss (GAAP) reached $13.3 million in Q2 2025, with adjusted EBITDA turned negative at $(6.1 million) in Q2 2025 as profitability and margins compressed during the business reset. Management reiterated full-year guidance and reported operating cash flow of $33.6 million in the second quarter of 2025 and an increased cash balance as of the end of Q2 2025, highlighting progress in cost control and strategic shift toward payer/provider and transportation business. These 10 stocks could mint the next wave of millionaires › DocGo (NASDAQ:DCGO), a company specializing in technology-enabled mobile health services and medical transportation, released its second quarter 2025 earnings report on August 7, 2025. The headline news was a marked year-over-year revenue drop, driven by the planned exit from high-margin government and migrant service contracts. Revenue (GAAP) was $80.4 million in Q2 2025, surpassing the consensus GAAP estimate of $77.6 million, while the bottom-line result was a net loss of $13.3 million (GAAP), yielding a loss per share of $(0.11) (GAAP) compared to the expected $(0.10) EPS. Overall, margins and profitability declined as the business transitioned toward more stable but lower-margin segments. Despite these challenges, management reaffirmed its full-year guidance, underscoring efforts to ramp up transportation and payer/provider partnerships, and reported an increase in cash balances to $128.7 million as of Q2 2025, up from $103.1 million at the end of Q1 2025 as receivables continued to be collected. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. About DocGo and Its Business Focus DocGo operates in the healthcare sector, delivering on-demand mobile health services, including in-home care and paramedic support, as well as non-emergency medical transportation. The company's platform combines technology, healthcare providers, and logistics to deliver care at patients' locations, streamlining healthcare access and cost. In recent years, DocGo relied heavily on large government and migrant-related contracts, which contributed high-margin, short-term revenue. With these winding down, DocGo's focus shifted to building out longer-term partnerships with health insurance payers and healthcare providers, and to expanding its transportation service contracts. Success in these areas will depend on the company's ability to scale up new business verticals, improve efficiency using its technology platform, and maintain compliance with complex healthcare regulations. Quarterly Review: Key Developments and Trends DocGo's second quarter results reflected a transitional phase. Total revenue (GAAP) fell 51.2% year over year, outpacing analyst estimates for GAAP revenue yet sharply down from Q2 2024 (Q2 2025 revenue was $80.4 million GAAP, compared to $164.9 million GAAP in Q2 2024), due largely to the wind-down of government and migrant services. Management explained, 'This decline was due to the planned wind-down of migrant-related programs.' The company had flagged this shift in previous guidance updates, removing government population health from its core outlook and resetting 2025 targets accordingly. Profitability suffered as the business mix changed. Adjusted EBITDA was negative at $(6.1 million), down from $17.2 million in adjusted EBITDA in Q2 2024, and the company posted a GAAP net loss of $13.3 million. Adjusted gross margin fell to 31.6%, compared to 33.9% (adjusted, non-GAAP) in Q2 2024. The company's cash flow from operations remained strong, generating $33.6 million, slightly below last year's figure but up from the first quarter of 2025. Cash and equivalents rose to $128.7 million as of the end of Q2 2025, helped by successful collection of legacy receivables from government contracts. Accounts receivable related to migrant work declined but remained sizable, standing at approximately $54 million as of the end of Q2 2025, which management expects to collect through year-end. Within business lines, transportation services proved most stable. Segment revenue was $49.6 million, up modestly compared to $48.2 million in Q2 2024, and management cited contract expansions, including a multi-year partnership with a leading New York academic medical system, with services launched after Q2 2025. This contract, supported by DocGo's software-as-a-service (SaaS) transportation management platform, is expected to boost trip volumes in the back half of the year. The mobile health segment—comprising in-home visits and payer/provider partnerships—generated $30.8 million in revenue, a steep drop from last year, as GAAP revenue declined from $164.9 million in Q2 2024 to $80.4 million. However, DocGo highlighted momentum in this segment's core activities: the number of patients assigned for care gap closure services rose from 900,000 in Q1 2025 to over 1.2 million, driven by new and expanded insurance partnerships. The company completed more in-home visits in the first half of 2025 than in all of 2024. Execution in payer/provider services remains a key investment area, with profitability expected to improve as scale increases and operational efficiencies are realized. SG&A (selling, general, and administrative) expenses continued to weigh on margins during this transition, but management initiated cost cuts and repurchased 2.5 million shares, making cuts to corporate overhead, resulting in an estimated $10 million in annual savings. Workforce reductions and further expense control measures are planned for the remainder of the year, aiming to support profitability in the longer term. Looking Ahead: Guidance and Risk Areas Management maintained 2025 revenue guidance at $300 million to $330 million, unchanged from the previous update. Adjusted EBITDA is still forecasted to be a loss in the range of $20 million to $30 million for the full year 2025. With another dip expected in Q3, and Q4 projected to be higher than Q3 but still below Q2 levels. The company aims for overall profitability by the second half of 2026, even without the contribution of new government contracts. Key watchpoints for the coming quarters include the pace at which DocGo can grow its payer/provider vertical, the ability to ramp margins in both mobile health and transportation, timely collection of outstanding receivables, and further reductions in SG&A costs. Any new government revenue or contract wins will be treated as additive and not factored into the current guidance. Management emphasized ongoing focus on technology upgrades, compliance, and operational scalability as critical for the next phase of business growth. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,046%* — a market-crushing outperformance compared to 181% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 4, 2025
